P2Y11 Antagonist B7508: Precision Tools for GPCR Signaling Research

Principle and Biochemical Foundations of the P2Y11 Antagonist

The P2Y11 antagonist (SKU: B7508) is a powerful cell signaling inhibitor targeting the P2Y11 receptor, a G protein-coupled receptor (GPCR) central to purinergic signaling in immunology and inflammation studies. Chemically identified as sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate, B7508 exhibits a molecular weight of 986.84 and dissolves readily in water at concentrations below 19.74 mg/ml.

Functionally, this antagonist blocks P2Y11-driven downstream events, including intracellular calcium mobilization and cyclic AMP (cAMP) accumulation, thereby modulating inflammation and immune cell behavior. Notably, recent evidence highlights its pivotal role in reversing invasive phenotypes in cancer models by interrupting purinergic signaling cascades, as shown in studies such as Liu et al. (2021) on breast cancer cell invasiveness.

Experimental Workflow: Step-by-Step Protocol Enhancements with B7508

1. Reagent Preparation and Handling

• Solubilization: Dissolve the beige solid directly in sterile water to a maximum of 19.74 mg/ml. For most cell-based assays, working concentrations range between 1–50 μM.
• Storage: Maintain unopened powder at -20°C. Prepare fresh solutions before each experiment, as B7508 solutions are not stable for extended storage—prompt usage mitigates degradation and ensures reproducibility.
• Shipping: The product is shipped on blue ice to preserve chemical integrity, especially for sensitive GPCR assays.

2. Cell-Based Assay Integration

• Cell Line Selection: B7508 has demonstrated efficacy across a spectrum of cell lines, including breast cancer (MCF-7, MDA-MB-231), immune cells, and primary human PBMCs.
• Treatment Protocol: Following cell seeding and overnight attachment, add B7508 at your optimized concentration (commonly 5–20 μM) 30–60 minutes prior to agonist stimulation.
• Endpoint Assays: Compatible with calcium flux, cAMP quantification, migration/invasion assays, and immunoblotting for pathway markers such as phosphorylated myosin light chain (MLC), as utilized in the Liu et al. study.

3. Comparative Protocol Optimization

• Parallel Inhibitor Controls: For pathway specificity, B7508 can be used alongside other pathway inhibitors (e.g., ROCK inhibitor Y27632, PLC inhibitor U73122) for dissection of complex signaling nodes, as exemplified in the referenced breast cancer study.
• Solution Handling: To minimize compound precipitation or loss of activity, use low-protein binding tubes and filter final working solutions through 0.22 μm filters if required for sensitive assays.

Advanced Applications and Comparative Advantages

1. Dissecting GPCR Signaling in Oncology and Immunology

The P2Y11 antagonist B7508 has emerged as a cornerstone for unraveling the role of purinergic signaling in disease progression. In the context of breast cancer, B7508 effectively reversed QPRT-induced cellular invasiveness and myosin light chain phosphorylation (Liu et al., 2021), highlighting its utility in modulating metastatic phenotypes. Its action as a G protein-coupled receptor antagonist provides precise temporal and dose-dependent inhibition of P2Y receptor signaling, facilitating nuanced studies of pathway crosstalk in both tumor and immune cell models.

Beyond oncology, B7508’s modulation of inflammation pathway signaling enables researchers to probe mechanisms underlying autoimmune and neuroinflammatory conditions, supporting both basic mechanistic insight and preclinical therapeutic exploration.

2. Comparative Insights and Resource Interlinking

B7508’s specificity and robustness have been contrasted and complemented in the literature. The review “P2Y11 Antagonist B7508: Advanced Tools for GPCR Signaling...” offers actionable protocols and troubleshooting guidance, complementing the present workflow focus with additional hands-on expertise. Meanwhile, “Rewiring Purinergic Signaling: Strategic Use of P2Y11 Ant...” extends the discussion to competitive benchmarking and translational strategies, illuminating how sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate distinguishes itself in the evolving landscape of GPCR research.

3. Quantified Performance and Benchmarking

In direct head-to-head studies, B7508 exhibits nanomolar to low micromolar potency for P2Y11 inhibition, with minimal off-target activity at concentrations up to 50 μM. In breast cancer models, the antagonist achieved up to 80% reduction in invasive migration when applied at 10 μM, as quantified in Matrigel invasion assays. These performance metrics underscore its reliability and translational relevance.

Troubleshooting and Optimization Tips

• Solubility Issues: If precipitation is observed, gently warm the solution to 37°C and vortex; avoid repeated freeze-thaw cycles which can degrade the compound.
• Batch Consistency: Validate each lot with a quick cAMP or calcium flux assay to ensure consistent P2Y11 receptor antagonism, particularly when switching suppliers or scaling up experiments.
• Off-Target Effects: Always include vehicle and non-targeted GPCR controls to distinguish B7508-specific effects, as highlighted in the workflow from “P2Y11 Antagonist B7508: Novel Insights into Inflammation ...”, which extends the utility of B7508 to inflammation pathway dissection.
• Rapid Degradation: Prepare working solutions immediately prior to use and discard any leftovers after each session to maintain maximal inhibitory activity.
• Assay Sensitivity: For high-content imaging or sensitive multi-well formats, perform a titration series to pinpoint the lowest effective concentration, reducing assay background and compound usage.

Future Outlook: Expanding the Horizon for P2Y11 Antagonist B7508

The P2Y11 antagonist B7508 is poised to play a transformative role in next-generation GPCR signaling studies. Its unique profile as a selective cell signaling inhibitor targeting P2Y11 receptor signaling opens avenues for detailed mechanistic investigation of autoimmune disease etiology and neuroinflammation. Integration with CRISPR-based genetic screens, single-cell analytics, and multiplexed pathway interrogation will accelerate the deconvolution of complex signaling networks.

Continued refinement of protocol guidelines, such as those outlined in “P2Y11 Antagonist B7508: Redefining Translational Strategi...”, ensures that translational researchers leverage the full potential of sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate in both disease modeling and future therapeutic development. As the field moves toward precision medicine, B7508’s role in modulating GPCR signaling pathway and P2Y receptor signaling will remain at the forefront of both basic and translational research.

For more details, product specifications, and batch-specific data, visit the official P2Y11 antagonist product page.